Lymphatic invasion (LI) identified by immunohistochemical (IHC) staining is common in primary cutaneous melanoma, and LI has been shown to be an independent prognostic factor in melanoma. Its prognostic significance in melanocytic tumors of uncertain malignant potential (MELTUMPs) has not been well characterized. This study included 32 patients with provisional diagnoses of MELTUMP. Lesions were evaluated for tumor thickness, the presence of ulceration, mitotic figures, mitotic figures at the base, tumor infiltrating lymphocytes, as well as peritumoral and intratumoral lymphatic density. Dual IHC staining was used to microscopically detect lymphatic endothelium (podoplanin) containing melanoma cells (S100), with the aid of multispectral imaging in select cases. Univariate analysis was performed to identify associations between clinical and pathologic variables and melanoma-related events. The 32 patients had a median follow-up of 111 months. Two patients subsequently died of melanoma-related disease, 1 died of unknown causes, 5 developed nodal metastases, and the remainder showed no evidence of progressive disease. LI was identified in 8/32 patients (25%) by dual IHC staining, which included the 2 patients who died of melanoma-related disease, 1 patient with bulky nodal metastasis, 1/4 patients with microscopic nodal metastases, and 4 patients who showed no evidence of progressive disease. The presence of LI was associated with melanoma metastases or melanoma-related death (P = 0.05). The presence of LI by dual IHC in MELTUMPs is associated with a poorer prognosis, specifically with melanoma metastasis, and may therefore serve as a useful prognostic factor for risk stratification of patients with these diagnostically challenging lesions.
A subset of bulky melanocytic lesions obscure the boundary between benign nevus and malignant melanoma and have long perplexed dermatopathologists because of their morphology and biological behavior, often eluding consensus in their diagnosis and their nomenclature. [1] [2] [3] Although characterized as "borderline melanomas," "minimal deviation melanoma," "dermalbased borderline melanocytic tumor," [4] [5] [6] and "atypical" counterparts to conventional nevi such as Spitz, blue, or deep penetrating nevi (in addition to many others), our preferred term for these lesions is "melanocytic tumors of uncertain malignant potential" (MELTUMP), as it aptly captures the diagnostic and prognostic challenge they represent. 2, [7] [8] [9] [10] MELTUMP is a provisional diagnosis; although one may favor a benign or malignant characterization, a definitive diagnosis is not always possible at initial presentation, and long-term (or perhaps life-long) clinical follow-up remains the only true evidence of biological behavior. These lesions often require expert consultation and frequently prompt aggressive management that would accompany a melanoma diagnosis.
Melanoma has a well-known propensity for lymph node metastasis. 11, 12 Lymphangiogenesis and lymphatic invasion (LI; defined as the presence of melanoma cell(s) within a lymphatic vessel) have been under increasing investigation in melanoma given the recent availability of antibodies specific for lymphatic endothelial cells. 13, 14 We and others have shown that LI detected by immunohistochemistry (IHC) in primary melanomas is common, ranging from 16% to 47%, 13, 15 whereas blood vascular invasion is uncommon, ranging from 1% to 3%. 16, 17 We recently presented evidence of lymphangiogenesis in areas with regression in the radial growth phase adjacent to vertical growth phase lesions, and the presence of LI in the area of radial growth phase regression may, at least in part, explain the association of regression with poorer prognosis. 18 More recently, we showed that LI is an independent adverse prognostic factor and significantly increases the risk of metastasis in melanoma. 19 We sought to determine the presence of LI by IHC in MELTUMPs, with the hypothesis that the presence of LI may serve as a negative prognostic marker of disease in these patients. In addition, lymphatic density (LD), both peritumorally and intratumorally, was assessed to study whether the extent of lymphangiogenesis in these lesions was associated with prognosis.
MATERIALS AND METHODS
Twenty-three cases with a provisional diagnosis of MELTUMP were identified from one of the coauthors' consult cases (D.E.E.). Diagnostic criteria for MEL-TUMP were discussed previously. 7, 9, 10 Nine additional cases with available residual tumor tissues were provided by another coauthor (L.C.). 2 All cases were reviewed by 2 pathologists (X.X., R.M.A.) and were confirmed to be MELTUMP lesions at initial presentation. Cases were also subcategorized as "spitzoid" (with morphology resembling Spitz tumor), "DPN-like" (resembling a deep penetrating nevus), or "nevoid" (resembling a banal or dysplastic nevus). No "blue nevus-like" lesions were present in this cohort. Clinical follow-up data were obtained from consultant physicians and patients through a protocol approved by the Institutional Review Board of the University of Pennsylvania. Lesions were evaluated for tumor thickness and the presence of ulceration, mitotic figures, mitotic figures at the base, and tumor infiltrating lymphocytes (TILs). Dual IHC staining was used to detect lymphatic endothelium (podoplanin, D2-40) and melanoma cells (S100 protein). The presence of LI was analyzed microscopically, with the aid of multispectral imaging (MSI). LI was defined as S100 protein-positive cells with melanoma cytology within a podoplanin-positive lymphatic space. Peritumoral and intratumoral LD were also assessed. Peritumoral LD was defined as the number of lymphatic spaces in a "hotspot" in 5 high-power (Â 400) fields within 2 mm of the tumor edge. Intratumoral LD was defined as the number of lymphatic spaces in a "hotspot" in 5 high-power fields within the tumor. IHC assays were performed on 5-mm-thick sections of formalin-fixed, paraffin-embedded tissue, and staining was done on a DakoCytomation Autostainer using the EnVision+HRP DAB system (DakoCytomation) according to manufacturer's recommendations. The D2-40 antibody (mouse monoclonal, 1:25 dilution; Signet Laboratories) that specifically detects a fixation-resistant epitope on podoplanin was used to decorate lymphatic endothelium. Melanocytes were identified using S100 protein antibody (rabbit polyclonal, 1:50; DakoCytomation). The antibody to lymphatic endothelium was visualized with the brown chromogen DAB (3,3-diaminobenzidine; DakoCytomation) and antibodies to melanoma cells with the red chromogen Nova Red (Vector Laboratories). IHC-stained slides cut from unstained slides or tissue blocks were reviewed by 2 pathologists (R.M.A., X.X.), who were blinded to clinical outcome. LI (present or absent) was defined as the presence anywhere within the primary tumor of S100-positive cell(s) with morphologic features of melanocytic tumor in lumens highlighted by podoplanin staining. Questionable instances were confirmed or refuted by use of MSI. Disagreements were resolved by consensus reading.
For MSI analysis, slides were examined using a Leica DMRA2 microscope (Leica Microsystems Inc.) equipped with planapochromatic lenses. Potential foci of LI were imaged at Â 200 through a liquid crystal filter using the Nuance Multispectral Imaging System (Cambridge Research and Instrumentation Inc.). Spectral data were acquired from 420 to 720 nm, and spectral unmixing was accomplished by Nuance software v1.42 and pure spectral libraries of individual chromogens (slides stained with only DAB, Nova red, or hematoxylin). Nonspecific background staining was subtracted from each image individually. To visualize several spectral markers simultaneously, images were then evaluated using unmixed images generated by the Nuance system.
Statistical analyses were performed using GraphPad Prism 5 (GraphPad Software Inc.). Unpaired t tests were used to evaluate correlations between LI and the tumor characteristics. The following cutoff values or distinctions were used for log rank survival analysis: LI absent or present, male or female sex, thickness of >2 mm, brisk or nonbrisk/absent TILs, mitoses at base present or absent, peritumoral LD median (>7), and intratumoral LD median (> 5). Multivariate analysis was also performed (Table 1) .
RESULTS
The median age of 32 patients was 31.5 years (range, 2 to 67 y), there were 16 male and 16 female patients, and the average tumor thickness was 2.46 mm ( Table 2) . Twenty-two lesions were categorized as "spitzoid," 9 as "nevoid," and 1 as "DPN like." Clinical follow-up period ranged from 4 to 276 months, with a median of 111 months. Of the 32 patients, 2 subsequently died of melanoma-related disease, 1 died of unknown causes, 5 developed nodal metastases (1 with bulky disease), and the remainder showed no evidence of progressive disease. LI was not recognized in any of the cases except through the use of double IHC staining. LI by our staining method was found in 8/32 cases (25%), including both cases in which patients died of melanoma-related disease (2/2, 100%), 2 patient with bulky nodal metastasis (1/1, 100%), 1 of 4 patients with microscopic nodal metastases (1/4), and 4 patients who showed no evidence of progressive disease (Figs. 1-3) . The presence of LI correlated with more aggressive clinical outcomes, defined as either 0.52 developing nodal metastases, distant metastases, or melanoma-related death as determined by the unpaired t test (P = 0.047). The incidence of a melanoma-related metastasis or death in the LI group was 57% (4/7) versus 16% (4/25) in the no LI group. LI was also associated with a significant melanoma-specific survival difference by log rank analysis (P = 0.03). None of the other parameters evaluated (age, tumor thickness, mitoses, mitoses at the base, ulceration, TILs, intratumoral, or peritumoral LD) demonstrated a statistically significant correlation with outcome or significant survival difference as determined by the unpaired t test or log rank analyses ( 
DISCUSSION
The purpose of this study was an attempt to validate the use of evaluating LI by dual IHC as a useful tool in ambiguous melanocytic lesions with vertical growth phase (MELTUMPs). In addition, we assessed LD to see whether this property correlated with outcome or other tumor characteristics. This particular subset of melanocytic lesions is fraught with controversy and minimal diagnostic reproducibility and agreement among dermatopathologists. There is some question whether the concept of "uncertainty" or "ambiguity" in melanocytic lesions is valid and can coexist with the pathologist's burden to make definitive diagnoses. 20, 21 However, it is in these present authors' collective opinion that there are particular lesions in which one cannot make a definitive diagnosis on the basis of accepted histopathologic criteria, and thus it is uncertain as to how a lesion will progress clinically. In a tutorial held at the XXIX Symposium of the International Society of Dermatopathology in Graz, Austria, Cerroni and colleagues (including M.C.M. and D.E.E.) looked at 57 ambiguous melanocytic lesions to assess both the diagnostic reproducibility of these lesions and the potential features that may help in the categorization of these tumors. Diagnostic consensus was found to be relatively uncommon, even among a group of international experts in melanocytic tumors, as 15.8% of the cases were either classified by the majority of the panelists as uncertain or the diagnoses were split equally between benign and malignant. 2 In addition, among the several histopathologic criteria examined in this exercise, only 3 were found statistically different in the 2 groups with favorable and unfavorable behavior on the basis of clinical follow-up: presence of mitoses, mitoses near the base, and inflammatory infiltrate. Our study evaluated these 3 criteria to test whether we could reproduce the same correlations with outcome; however, we failed to find statistically significant associations. Our cohort had fewer cases with clinical follow-up and fewer with unfavorable outcomes or aggressive behavior; Dr Cerroni's cohort comprised 57 cases with clinical followup and several patients with bulky nodal metastases, visceral metastases, and melanoma-related death. Nine cases from that cohort are also part of our study; however, no tumor characteristics were factored into the analysis of our cohort other than LI and LD, age, and sex. The difference between the studies is likely because of the number of cases and heterogenous nature of MELTUMP cases.
Our statistically significant findings include an association between LI as identified by our method and "aggressive behavior" as defined by nodal metastases and melanoma-specific death. Another interesting statistically significant correlation is the presence of TILs with increased levels of LD. This phenomenon appears to link lymphocytic infiltrate with lymphangiogenesis in melanoma. This finding parallels our previous finding of the presence of lymphangiogenesis in the area of radial growth phase regression, suggesting that lymphocytes or other inflammatory cells may secrete cytokines inducing lymphangiogenesis. Nevertheless, the underlying mechanism of the phenomenon is still unclear, and we are currently investigating this in our research laboratory.
LI was present in both cases of melanoma-related death, suggesting high sensitivity of LI in MELTUMPs to detect unequivocal malignant behavior. In both cases, lymphatic vessels were difficult to appreciate on standard hematoxylin and eosin staining. LI was also present in 1 case with bulky nodal metastasis (1/1, 100%) and in 1 of 4 patients with microscopic nodal metastases (1/4, 25%). The significance of tumor deposits in lymph nodes is also a controversial matter in MELTUMPs. Unfortunately, as the cases were received in consultation from different regions, treatment of these lesions was not consistent; some patients received local wide excision and never returned to the dermatologist, whereas others underwent sentinel lymph node (SLN) biopsy and subsequent lymphadenectomy. Although SLN biopsy was performed in several of these cases, and is a useful prognostic tool in the management of those with melanoma, the role of SLN biopsy in MELTUMPs has not yet been established. Recent studies have looked at concurrent tumor deposits in lymph nodes of MELTUMPs, mostly of atypical spitzoid lesions, and have shown that these lesions rarely progress to overt malignancy. A study of atypical spitzoid tumors at one institution showed that roughly half of 67 cases contained tumor deposits in lymph nodes, whereas only 1 patient of the subset died of progressive disease. 22 Other studies have presented similar findings. 15, [22] [23] [24] [25] It appears that lymph node involvement in MELTUMP-like lesions occurs frequently and is perhaps indicative of low malignant potential, and the incidence of subsequent deadly disease is low. Nevertheless, most of these studies have a relatively short follow-up time. The fact remains that melanoma can afflict both the young and the old and appear nevoid, spitzoid, or DPN-like or resemble any other benign counterpart, and metastasis could manifest several decades later in life. 26, 27 For a young child, 1 to 2 decades of disease-free follow-up does not necessarily preclude the potential for disease progression into adulthood. What LI by dual IHC may offer is definitive evidence of lymphovascular invasion, which excludes the possibility of a mechanical migration or colonization of a lymph node by a benign nevus, which may hold more prognostic relevance on the basis of our data. Fur-thermore, as SLN biopsy is not currently standard of care in these lesions and can potentially cause morbidity especially with completion lymphadenectomy, our LI assay could potentially provide a surrogate marker for SLN positivity. Further study would be needed to validate these assertions.
Finally, the study illustrates the difficulty in categorizing a subset of lesions that are heterogenous but share a common diagnostic uncertainty because of histopathologic features that straddle benign and malignant characterizations. As molecular technology, currently array-comparative genomic hybridization and fluorescence in situ hybridization (and perhaps later next generation sequencing modalities), may provide useful supplemental data, currently no single histopathologic or ancillary criterion can establish a diagnosis. Unfortunately, the only reliable indicator of malignancy in melanocytic lesions is the development of distant metastases. On the basis of our findings, our method of LI by dual IHC may provide a relatively cheap, noninvasive, prognostic adjunct in determining which lesions are capable of distant metastasis and fatal outcomes.
